Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -12,345 | -7,216 | -11,258 | -27,377 |
| Depreciation | 87 | 88 | 89 | 187 |
| Stock-based compensation expense | 1,660 | 1,261 | 1,384 | 3,048 |
| Amortization of right-of-use assets | 134 | 135 | 135 | 270 |
| Accretion of discounts on short-term investments, net | 93 | 158 | 252 | 438 |
| Accounts receivable and unbilled receivable | 9 | -72 | -272 | -247 |
| Prepaid expenses and other current assets | -606 | 911 | -1,080 | -388 |
| Other assets | 295 | 0 | 148 | 332 |
| Accounts payable and accrued liabilities | -1,847 | 940 | -1,961 | 3,223 |
| Operating lease liabilities | -186 | -178 | -175 | -338 |
| Net cash used in operating activities | -12,288 | -5,967 | -10,834 | -21,122 |
| Sales of short-term investments | NaN | 899 | 0 | 1,236 |
| Capital expenditures | NaN | 0 | 18 | 26 |
| Maturities of short-term investments | 15,826 | 16,572 | 19,519 | 35,020 |
| Purchases of short-term investments | 12,569 | 6,722 | 9,341 | 55,797 |
| Net cash provided by (used in) investing activities | 3,257 | 10,749 | 10,160 | -19,567 |
| Proceeds from sales of common stock, net of expenses of 0 and 3,286, respectively | NaN | 0 | NaN | NaN |
| Proceeds from exercise of warrants, net of expense of 169 and 0, respectively | NaN | 2,088 | NaN | NaN |
| Proceeds from exercise of options | 105 | 465 | 25 | 3 |
| Net cash provided by financing activities | 105 | 2,553 | 25 | 3 |
| Net change in cash and cash equivalents | -8,926 | 7,335 | -649 | -40,686 |
| Cash and cash equivalents - beginning of period | 17,470 | 10,135 | 51,470 | NaN |
| Cash and cash equivalents - end of period | 8,544 | 17,470 | 10,135 | NaN |